Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC

J Thorac Oncol. 2020 Jul;15(7):e124-e127. doi: 10.1016/j.jtho.2020.03.020.

Authors

Viola W Zhu¹, Russell Madison², Alexa B Schrock², Sai-Hong Ignatius Ou³

Affiliations

¹ Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, California.
² Foundation Medicine Inc., Cambridge, Massachusetts.
³ Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, California. Electronic address: siou@hs.uci.edu.

PMID: 32593453
DOI: 10.1016/j.jtho.2020.03.020

No abstract available

Publication types

Letter
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Mutation
Oncogene Proteins, Fusion / genetics
Proto-Oncogene Proteins c-ret / genetics
Solvents

Substances

KIF5B-RET fusion protein, human
Oncogene Proteins, Fusion
Solvents
Proto-Oncogene Proteins c-ret
RET protein, human